Putting the Pieces Together: Necrolytic Migratory Erythema and the Glucagonoma Syndrome

被引:0
作者
Stephanie A. C. Halvorson
Erin Gilbert
R. Samuel Hopkins
Helen Liu
Charles Lopez
Michael Chu
Marie Martin
Brett Sheppard
机构
[1] Oregon Health & Science University,Division of Hospital Medicine, Department of Medicine
[2] Oregon Health & Science University,Department of Surgery
[3] Oregon Health & Science University,Department of Dermatology
[4] Oregon Health & Science University,Knight Cancer Institute
[5] Oregon Health & Science University,Division of Endocrinology, Diabetes and Clinical Nutrition, Department of Medicine
[6] Oregon Health & Science University,undefined
来源
Journal of General Internal Medicine | 2013年 / 28卷
关键词
glucagonoma; neuroendocrine tumors; necrolytic migratory erythema;
D O I
暂无
中图分类号
学科分类号
摘要
Glucagonomas are slow-growing, rare pancreatic neuroendocrine tumors. They may present with paraneoplastic phenomena known together as the “glucagonoma syndrome.” A hallmark sign of this syndrome is a rash known as necrolytic migratory erythema (NME). In this paper, the authors describe a patient with NME and other features of the glucagonoma syndrome. The diagnosis of this rare tumor requires an elevated serum glucagon level and imaging confirming a pancreatic tumor. Surgical and medical treatment options are reviewed. When detected early, a glucagonoma is surgically curable. It is therefore imperative that clinicians recognize the glucagonoma syndrome in order to make an accurate diagnosis and refer for treatment.
引用
收藏
页码:1525 / 1529
页数:4
相关论文
共 94 条
  • [1] Batcher E(2011)Pancreatic neuroendocrine tumors Endocr Res 36 35-43
  • [2] Madaj P(2007)Population-based study of islet cell carcinoma Ann Surg Oncol 14 3492-3500
  • [3] Gianoukakis AG(2011)Glucagonoma and the glucagonoma syndrome – cumulative experience with an elusive endocrine tumour Clin Endocrinol 74 593-598
  • [4] Yao J(2001)Clinical significance of blood chromogranin A measurement in neuroendocrine tumours Ann Oncol 12 S69-S72
  • [5] Eisner M(2007)Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years Med Oncol 24 330-63
  • [6] Leary C(1996)The glucagonoma syndrome. Clinical and pathologic features in 21 patients Medicine 75 53-361
  • [7] Eldor R(1981)The glucagonoma syndrome: clinical features, diagnosis, and treatment Endocr Rev 2 347-831
  • [8] Glaser B(2002)Peripheral amino acid and fatty acid infusion for the treatment of necrolytic migratory erythema in the glucagonoma syndrome Clin Endocrinol 57 827-320
  • [9] Fraenkel M(2001)The glucagonoma syndrome: a review of its features and discussion of new perspectives Am J Med Sci 321 306-873
  • [10] Doviner V(1998)Iatrogenic necrolytic migratory erythema: a case report and review of nonglucagonoma-associated necrolytic migratory erythema J Am Acad Dermatol 38 866-537